Related Experiment Video
Updated: Jul 24, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Targeting HIF-2 Alpha in Renal Cell Carcinoma
Ramsha Ahmed1, Moshe C Ornstein2
1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI, 53226, USA.
Opinion Statement:
Current treatment options for patients with metastatic renal cell carcinoma (mRCC) are limited to immunotherapy with checkpoint inhibitors and targeted therapies that inhibit the vascular endothelial growth factor receptors (VEFG-R) and the mammalian target of rapamycin (mTOR). Despite significantly improved outcomes over the last few decades, most patients with mRCC will ultimately develop resistance to these therapies, thus highlighting the critical need for novel treatment options. As part of the VHL-HIF-VEGF axis that rests at the foundation of RCC pathogenesis, hypoxia-inducible factor 2α (HIF-2α) has been identified as a rationale target for mRCC treatment. Indeed, one such agent (belzutifan) is already approved for VHL-associated RCC and other VHL-associated neoplasms. Early trials of belzutifan indicate encouraging efficacy and good tolerability in sporadic mRCC as well. The potential inclusion of belzutifan and other HIF-2α inhibitors into the mRCC treatment armamentarium either as a single agent or as combination therapy would be a welcome addition for patients with mRCC.
Insights
Hypoxia-inducible factor 2α (HIF-2α) inhibitors show promise for treating metastatic renal cell carcinoma (mRCC). Belzutifan, an approved HIF-2α inhibitor, demonstrates efficacy and tolerability in early mRCC trials, offering new therapeutic options.
Area of Science:
- Oncology
- Medical Science
Background:
- Current metastatic renal cell carcinoma (mRCC) treatments include immunotherapy and targeted therapies (VEGF-R, mTOR inhibitors).
- Therapy resistance is common, necessitating novel treatment strategies for mRCC.
- The VHL-HIF-VEGF pathway is crucial in RCC pathogenesis, identifying HIF-2α as a potential therapeutic target.
Purpose of the Study:
- To evaluate the potential of hypoxia-inducible factor 2α (HIF-2α) inhibitors as a novel treatment for metastatic renal cell carcinoma (mRCC).
- To discuss the role of belzutifan, an approved HIF-2α inhibitor, in the context of mRCC treatment.
Main Methods:
- Review of current treatment landscape for mRCC.
- Analysis of the VHL-HIF-VEGF pathway in RCC.
- Examination of early clinical trial data for belzutifan in sporadic mRCC.
Main Results:
- Belzutifan is approved for VHL-associated RCC and neoplasms.
- Early trials suggest belzutifan has encouraging efficacy and good tolerability in sporadic mRCC.
- HIF-2α inhibitors represent a promising new class of drugs for mRCC.
Conclusions:
- HIF-2α inhibitors, including belzutifan, offer a rationale and potentially effective new treatment avenue for mRCC.
- Belzutifan may be utilized as a single agent or in combination therapy for mRCC.
- Further investigation into HIF-2α inhibitors is warranted to expand treatment options for mRCC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:24Regulation of Angiogenesis and Blood Supply